2022
Utilization and Survival Impact of Hypofractionated Radiotherapy in Stage I Non-small Cell Lung Cancer
Saeed N, Jin L, Amini A, Verma V, Lester-Coll N, Chen P, Decker R, Park H. Utilization and Survival Impact of Hypofractionated Radiotherapy in Stage I Non-small Cell Lung Cancer. American Journal Of Clinical Oncology 2022, 46: 66-72. PMID: 36662872, DOI: 10.1097/coc.0000000000000974.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerStage I non-small cell lung cancerOverall survivalCell lung cancerLung cancerStereotactic body radiation therapyNational Cancer DatabaseLog-rank testBody radiation therapyOptimal fractionation scheduleMultivariable modeling techniquesOS benefitHypofractionated radiotherapySurvival impactMultivariable analysisCox regressionCancer DatabaseRetrospective analysisFractionation schedulesRadiation therapyHFRTPatientsCFRTRadiotherapyKaplan-Meier estimator
2021
Survival impact of bowel resection at the time of interval cytoreductive surgery for advanced ovarian cancer
McNamara B, Guerra R, Qin J, Craig A, Chen L, Varma M, Chapman J. Survival impact of bowel resection at the time of interval cytoreductive surgery for advanced ovarian cancer. Gynecologic Oncology Reports 2021, 38: 100870. PMID: 34646929, PMCID: PMC8496105, DOI: 10.1016/j.gore.2021.100870.Peer-Reviewed Original ResearchInterval cytoreductive surgeryProgression-free survivalAdvanced ovarian cancerBowel resectionCytoreductive surgeryOvarian cancerKaplan-Meier survival analysisThree-year survivalIncreased risk of mortalityLonger hospital stayCox proportional hazards modelsLong-term sequelaeRisk of mortalityProportional hazards modelInterval cytoreductionNeoadjuvant cyclesR0 resectionNeoadjuvant chemotherapyConfounding variables of ageASA scoreBlood transfusionHospital staySurvival impactPoor prognosisTumor Registry
2020
A Single-Institution Experience of Induction 5-Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin Followed by Surgery Versus Consolidative Radiation for Borderline and Locally Advanced Unresectable Pancreatic Cancer.
Cecchini M, Miccio JA, Pahade J, Lacy J, Salem RR, Johnson SB, Blakaj A, Stein S, Kortmansky JS, Johung KL. A Single-Institution Experience of Induction 5-Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin Followed by Surgery Versus Consolidative Radiation for Borderline and Locally Advanced Unresectable Pancreatic Cancer. Pancreas 2020, 49: 904-911. PMID: 32658074, DOI: 10.1097/mpa.0000000000001592.Peer-Reviewed Original ResearchConceptsPancreatic ductal adenocarcinomaLA PDACUnresectable pancreatic ductal adenocarcinomaInduction FOLFIRINOXConsolidative radiotherapyOverall survivalAdvanced unresectable pancreatic ductal adenocarcinomaSingle-center retrospective reviewMeaningful survival benefitMedian overall survivalUnresectable pancreatic cancerR0 resection rateKaplan-Meier methodSingle institution experienceBenefits of surgeryLog-rank testConsolidative radiationDefinitive radiationLA patientsPreoperative radiationResection rateSurgery patientsSurvival benefitSurvival impactImproved survivalDoes delay in time to surgery impact outcome in renal cell carcinoma: Analysis based on tumor size utilizing the National Cancer Database.
Patel D, Ghali F, Meagher M, Bradshaw A, Patel S, Murphy J, Derweesh I. Does delay in time to surgery impact outcome in renal cell carcinoma: Analysis based on tumor size utilizing the National Cancer Database. Journal Of Clinical Oncology 2020, 38: 664-664. DOI: 10.1200/jco.2020.38.6_suppl.664.Peer-Reviewed Original ResearchMultivariable Cox proportional hazardsNational Cancer DatabaseRenal cell carcinomaKaplan-Meier analysisYears of ageTumor sizeSurgery delayWorse OSOverall survivalHealthy patientsCell carcinomaCancer DatabaseLocalized Renal Cell CarcinomaNon-private insuranceTumor size 2Charlson comorbidity scoreCox proportional hazardsComorbidity scoreSurgical treatmentSurvival impactMedian timeEntire cohortFourth quartileBlack raceActive surveillance
2018
To chelate or not to chelate in MDS: That is the question!
Zeidan AM, Griffiths EA. To chelate or not to chelate in MDS: That is the question! Blood Reviews 2018, 32: 368-377. PMID: 29602612, DOI: 10.1016/j.blre.2018.03.002.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsIron chelation therapyMyelodysplastic syndromeIron overloadMDS patientsChronic transfusion supportAcute myeloid leukemiaBone marrow failureDisease-related alterationsTransfusion supportSurvival impactRandomized trialsInferior outcomesMyeloid leukemiaChelation therapyClinical consequencesMarrow failurePatientsHeterogeneous groupIron metabolismTherapyInherent risksSyndromePhysical manifestationsLeukemiaHemopathies
2017
A call for action: Increasing enrollment of untreated patients with higher‐risk myelodysplastic syndromes in first‐line clinical trials
Zeidan AM, Stahl M, Sekeres MA, Steensma DP, Komrokji RS, Gore SD. A call for action: Increasing enrollment of untreated patients with higher‐risk myelodysplastic syndromes in first‐line clinical trials. Cancer 2017, 123: 3662-3672. PMID: 28759108, DOI: 10.1002/cncr.30903.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsHigh-risk myelodysplastic syndromeAZA-001 trialClinical trialsMinimal survival gainsLarge randomized trialsManagement of patientsPopulation-based studyClinical trial enrollmentQuality of lifeMonotherapy armMedian survivalRandomized trialsSurvival impactTrial enrollmentSurvival gainMyelodysplastic syndromeRegistry analysisAggressive malignancyPatientsNatural historyRoutine useTrialsSurvivalEnrollmentHMAs
2016
Adjuvant chemotherapy and overall survival in adult medulloblastoma
Kann BH, Lester-Coll NH, Park HS, Yeboa DN, Kelly JR, Baehring JM, Becker KP, Yu JB, Bindra RS, Roberts KB. Adjuvant chemotherapy and overall survival in adult medulloblastoma. Neuro-Oncology 2016, 19: 259-269. PMID: 27540083, PMCID: PMC5464064, DOI: 10.1093/neuonc/now150.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCerebellar NeoplasmsChemoradiotherapy, AdjuvantChemotherapy, AdjuvantCraniospinal IrradiationFemaleFollow-Up StudiesHumansMaleMedulloblastomaMiddle AgedNeoplasm StagingPrognosisRadiotherapy, AdjuvantSurvival RateYoung AdultConceptsGy craniospinal irradiationCraniospinal irradiationOverall survivalM0 patientsAdjuvant chemotherapyAdult MBMultivariable Cox proportional hazard modelingHigh-dose craniospinal irradiationNational Cancer Data BaseCox proportional hazard modelingSuperior overall survivalPlanned subgroup analysisMultivariable logistic regressionNational database analysisLog-rank testProportional hazard modelingPediatric medulloblastoma patientsCSI dosesPostoperative chemotherapySurgical resectionSurvival impactYear OSMultivariable analysisSubgroup analysisRisk factors
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply